A randomized phase III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for participants with painful non-spine bone metastases (NCT06391242).

A Arjun Sahgal T Tim Nguyen (London Health Sciences Centre, London, ON, Canada) L Laura Masucci (Centre Hospitalier de l’Universite de Montreal, Montreal, Canada) K Kristopher Dennis (Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada) E Emma Dunne (BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada) A Anand Swaminath (Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada) I Isabelle Thibault (CHU de Quebec-Université Laval, Quebec, Canada) C Chiaojung Jillian Tsai (Princess Margaret Hospital, University Health Network, Toronto, ON, Canada) P Pejman Maralani (Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada) M Michael Donald Brundage (Cancer Centre Southeastern Ontario At KGH, Kingston, ON, Canada) M Marc Kerba (Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB, Canada) J Joel Lefebvre (Canadian Cancer Trials Group, Kingston, ON, Canada) W Wei Tu (State Key Laboratory of Metastable Materials Science and Technology) W Wendy R. Parulekar (Canadian Cancer Trials Group, Kingston, ON, Canada)

Abstract

TPS12141 Background: Stereotactic body radiotherapy (SBRT) is efficacious in the treatment of painful spinal metastases [1]. Data are required regarding the efficacy feasibility, toxicity and clinical outcomes associated with SBRT in patients with painful non-spine bone metastases prior to widespread adoption of this technique. Methods: This is a Canadian Cancer Trials Group led multi-centre, phase III randomized controlled trial comparing SBRT to conventional palliative external beam radiotherapy (CRT) in patients with solid tumours and a dominant painful non-spine bone metastasis (worst pain score >2). Treatment arms: EBRT 20Gy/5fr (control) versus SBRT 35 Gy/5fr or 30Gy/5fr (experimental). Primary objective : To compare 3-month complete pain response (CPR) rate and analgesic intake assessed using the International Consensus on Palliative Radiotherapy Endpoints [2]. Secondary objectives evaluate pain response pattern at 1, 3 and 6 months and assess re-irradiation rates, fracture incidence within RT target site, incidence of Grade > 2 adverse events, image-based local control, and patient reported outcomes (EORTC QLQ-C30 and QLQ-BM22). Statistical design: The target accrual is 230 patients, randomized 1:1. The trial is powered at 80% with a two-sided alpha of 0.05 to detect an improvement in the CPR rate from 17% (CRT) to 34% (SBRT), accounting for a 15% missing data rate. Conduct to Date : Study was activated on June 26, 2024. Supported by CCS grant # 707213. [1] Sahgal, Arjun, et al. "Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial." The Lancet Oncology 22.7 (2021): 1023-1033. [2] Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, Hahn C, van der Linden Y, Hartsell W, Kumar E; International Bone Metastases Consensus Working Party. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1730-7. doi: 10.1016/j.ijrobp.2011.02.008. Epub 2011 Apr 12. PMID: 21489705. Clinical trial information: NCT06391242 .

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (14)

A

Arjun Sahgal

T

Tim Nguyen

London Health Sciences Centre, London, ON, Canada

L

Laura Masucci

Centre Hospitalier de l’Universite de Montreal, Montreal, Canada

K

Kristopher Dennis

Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada

E

Emma Dunne

BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada

A

Anand Swaminath

Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada

I

Isabelle Thibault

CHU de Quebec-Université Laval, Quebec, Canada

C

Chiaojung Jillian Tsai

Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

P

Pejman Maralani

Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

M

Michael Donald Brundage

Cancer Centre Southeastern Ontario At KGH, Kingston, ON, Canada

M

Marc Kerba

Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB, Canada

J

Joel Lefebvre

Canadian Cancer Trials Group, Kingston, ON, Canada

W

Wei Tu

State Key Laboratory of Metastable Materials Science and Technology

W

Wendy R. Parulekar

Canadian Cancer Trials Group, Kingston, ON, Canada